The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-01. Anything still debated is marked as such rather than presented as settled.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
=== Importance in cancer biology === ITGA1 has shown to be an important regulator of cancer progression because malignant cells frequently exploit integrin-mediated ECM signaling to promote survival, invasion, metastasis, and therapy resistance. Dysregulated integrin signaling is associated with tumor development across multiple types of cancer, making ITGA1 a potential biomarker and therapeutic target. In PDAC, ITGA1 contributes to tumor progression by linking collagen-rich ECM environments with intracellular signaling pathways that support EMT, metastatic dissemination and survival. ITGA1 was identified as part of a protein network associated with PDAC progression emphasizing its importance in tumor biology. In retinoblastoma, ITGA1 is a possible therapeutic target because ITGA1 expression promotes the same functions of tumor cells through activation of downstream signaling pathways like FAK and STAT3. Pharmacological or genetic inhibition of ITGA1 reduces tumor progression, exhibiting the potential importance of targeting ITGA1-associated signaling pathways in pediatric cancers. In glioma, ITGA1 contributes to treatment resistance by promoting cell survival signaling. Increased ITGA1 activity supports activation of the PI3K/AKT pathway and anti-apoptotic signaling through Bcl-2, promoting resistance toward temozolomide. The involvement of ITGA1 in drug resistance highlights its role in regulating tumor cell adaptation to therapeutic stress.
Deficiency of VWF, therefore, shows primarily in organs with extensive small vessels, such as skin, gastrointestinal tract, and uterus. In angiodysplasia, a form of telangiectasia of the colon, shear stress is much higher than in average capillaries, and the risk of bleeding is increased concomitantly. In more severe cases of type 1 VWD, genetic changes are common within the VWF gene and are highly penetrant. In milder cases of type 1 VWD, a complex spectrum of molecular pathology may exist in addition to polymorphisms of the VWF gene alone. The individual's ABO blood group can influence presentation and pathology of VWD. Those individuals with blood group O have a lower mean level than individuals with other blood groups. Unless ABO group-specific VWF:antigen reference ranges are used, normal group O individuals can be diagnosed as type I VWD, and some individuals of blood group AB with a genetic defect of VWF may have the diagnosis overlooked because VWF levels are elevated due to blood group.
==== Television ==== Grey's Anatomy, a long-running TV series, approached the topic of EDS in its 13th season. In the episode "Falling Slowly", the show's doctors are confronted with confusion when faced with diagnosing a patient. Due to complex and contradicting symptoms presented by the patient, the show's doctors ultimately give the diagnosis of EDS. This episode was based on conversations held by producers who talked with a patient and doctor who have EDS.
== Critical response == Reception has varied widely according to its use, ranging from praise for its help immersing a player in the game, with titles such as Half-Life 2 and franchises such as Mario and The Legend of Zelda frequently cited, while the protagonist's lack of communication has at times been noted as hindersome to plot development, as in one reviewer's comments on Grand Theft Auto III, or multiple accounts on the Crash Bandicoot franchise. Others have stated that real immersion in a game would require a character to speak, since in such situations, the player would naturally vocalize and the protagonist does not. CJ Miozzi of The Escapist called franchises that still use the technique a "crutch" for bad storytelling, saying "just as narration has become a hallmark of terrible movies through improper use, silent protagonists have become the trademarks of a weak storyline in a game."
Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca. The most common side effects include infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite. Dapagliflozin/saxagliptin/metformin was approved for medical use in the United States in May 2019, and in the European Union in November 2019. Its marketing authorisation was withdrawn in the European Union in August 2020, and its approval was withdrawn in the US in April 2021, in both cases at the request of AstraZeneca.
Sources: en.wikipedia.org
Pantothenic acid is a water-soluble vitamin, one of the B vitamins. It is synthesized from the amino acid β-alanine and pantoic acid (see biosynthesis and structure of coenzyme A figures). Unlike vitamin E or vitamin K, which occurs in several chemically related forms known as vitamers, pantothenic acid is only one chemical compound. It is a starting compound in the synthesis of coenzyme A (CoA), a cofactor for many enzyme processes.
Several groups of animals have formed symbiotic relationships with photosynthetic algae. These are most common in corals, sponges, and sea anemones. Scientists presume that this is due to the particularly simple body plans and large surface areas of these animals compared to their volumes. In addition, a few marine mollusks, such as Elysia viridis and Elysia chlorotica, also maintain a symbiotic relationship with chloroplasts they capture from the algae in their diet and then store in their bodies (see Kleptoplasty). This allows the mollusks to survive solely by photosynthesis for several months at a time. Some of the genes from the plant cell nucleus have even been transferred to the slugs, so that the chloroplasts can be supplied with proteins they need to survive. An even closer form of symbiosis may explain the origin of chloroplasts. Chloroplasts have many similarities with photosynthetic bacteria, including a circular chromosome, prokaryotic-type ribosome, and similar proteins in the photosynthetic reaction center. The endosymbiotic theory suggests that photosynthetic bacteria were acquired (by endocytosis) by early eukaryotic cells to form the first plant cells. Therefore, chloroplasts may be photosynthetic bacteria that adapted to life inside plant cells. Like mitochondria, chloroplasts possess their own DNA, separate from the nuclear DNA of their plant host cells and the genes in this chloroplast DNA resemble those found in cyanobacteria. DNA in chloroplasts codes for redox proteins such as those found in the photosynthetic reaction centers.
Corticotropic releasing hormone (CRH): stimulates ACTH secretion Thyrotropin releasing hormone (TRH): stimulates TSH and prolactin secretion Growth hormone releasing hormone (GHRH): stimulates GH secretion Somatostatin: inhibits GH (and other hormone) secretion Gonadotropin releasing hormone (GnRH): stimulates FSH and LH secretion Prolactin releasing hormone (PRH): stimulates PRL secretion Prolactin inhibiting hormone (dopamine): inhibits PRL secretion These hypothalamic hormones are secreted in pulses. They act on specific membrane receptors. They are also glycoproteins. They stimulate:
=== Government efficiency === In 1997, Rolling Stone published a comprehensive snapshot of the US government's implementation of the war on drugs, spanning 44 federal agencies and hundreds of thousands of government workers, and without unified management, oversight, or cohesive strategy. Among the agencies there were over a dozen separate drug intelligence operations. The White House's Office of National Drug Control Policy, home of the drug czar and ostensibly the coordinating agency, had a staff of 150, and a $36 million budget; the overall federal drug war budget for 1998 was $16 billion. Most of the agencies involved did not report to the ONDCP, instead to one of 13 congressional appropriations subcommittees. The largest single share of the budget, $2 billion, went to the Bureau of Prisons. Federal agencies also passed on billions of anti-drug dollars to the states, with little oversight or accountability. In 2024, the ONDCP requested $461 million of a $46 billion federal budget allocated across some 50 federal agencies.
Sources: en.wikipedia.org
==== Polar uncharged ==== The polar, uncharged amino acids serine (Ser, S), threonine (Thr, T), asparagine (Asn, N) and glutamine (Gln, Q) readily form hydrogen bonds with water and other amino acids. They do not ionize in normal conditions, a prominent exception being the catalytic serine in serine proteases. This is an example of severe perturbation, and is not characteristic of serine residues in general. Threonine has two chiral centers, not only the L (2S) chiral center at the α-carbon shared by all amino acids apart from achiral glycine, but also (3R) at the β-carbon. The full stereochemical specification is (2S,3R)-L-threonine. Because of the presence of phenolic hydroxyl group with a pKa = ~10, tyrosine is best classified as a neutral polar amino acid, but with amphipathic character that makes it less polar than classical small polar amino acid residues.
=== Off-label promotion === Although some small, non-controlled studies in the 1990s—mostly sponsored by gabapentin's manufacturer—suggested that treatment for bipolar disorder with gabapentin may be promising, the preponderance of evidence suggests that it is not effective.
Schmidt praised the "high, clear and immensely rousing singing" on This Is Not Supposed To Be Positive. Chloe Leonard of Distorted Sound Magazine described "Naive" as "a sludge infused track that really showcases frontman Cédric Toufouti's impressive vocal range". Regarding A Loner, Toufouti and Igorrr's female lyrical singer spent some time together so she could teach him vocal techniques. In 2022, Desgroux described Toufouti's voice as "clear and ultra-melodic". David wrote that his singing on A Loner expresses "sadness without being tearful and loneliness without calling pity". A staff reviewer at Metal Storm felt that A Loner's "grunge-like" vocals are slightly too pronounced for that sound, though this does not hinder immersion; on the contrary, the ensuing contrast makes "the album more interesting". Webb said that the bassline coupled with the guitar tones on "An Ode To Breakdown" provides "the perfect platform" for Toufouti "to lay his beautiful, soulful singing over". In their review of Hangman's Chair's concert at DesertFest 2022 in the UK, Davey and Ruskell wrote that the band's music "culminate[s] in soaring riffs which serve to bolster the raw emotion of Cédric Toufouti's cleanly sung vocals". On Saddiction, Toufouti had to change his guitar tuning to match the Bass VI's sound and, consequently, adapt his vocal style. Thus, he went up into a higher pitch range more often and for longer durations, adding extra "tension" to certain riffs, he said.
Samson admitted that she was not familiar with the topic, but found it to be really interesting. She also explained that Mia has "a bit of tunnel vision" and feels that adopting a child will solve her problems, where Ari is more realistic about their situation. Samson believed Mia was using it as a way to channel her grief. Later scenes see Ari and Mia discussing adoption with John because he adopted his son, and while his experience is different from what Ari and Mia's would be, he gives them hope. The couple soon realise that Ari's criminal record might put a halt to their plans. Samson said "It just makes Mia more determined! Ari is quite worried about it from early on, but nothing is going to stop Mia..." In addition to this, Jasmine Delaney (Sam Frost) offers to sell the gym to Mia, which excites her as she would have something of her own and it will look good on the adoption application. The couple later become engaged, after Ari proposes to Mia. Barrett commented that her character is "ecstatically happy" for her mother and Ari, as she knows how much they love each other. Towards the end of 2021, producers introduced Chloe's biological father Matthew Montgomery (James Sweeny). This also led to further exploration of Mia's backstory, as it emerges that Matthew sexually assaulted her the night Chloe was conceived. A spokesperson for the serial told Sarah Ellis (Inside Soap) that Chloe has always seen Ari as a father figure because he has been in her life since she was young.
== Indications == Amifostine is used therapeutically to reduce the incidence of neutropenia-related fever and infection induced by DNA-binding chemotherapeutic agents including alkylating agents (e.g. cyclophosphamide) and platinum-containing agents (e.g. cisplatin). It is also used to decrease the cumulative nephrotoxicity associated with platinum-containing agents. Amifostine is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer. Amifostine was originally indicated to reduce the cumulative renal toxicity from cisplatin in non-small cell lung cancer. However, while nephroprotection was observed, the probability that amifostine could protect tumors could not be excluded. Additional data have shown that amifostine-mediated tumor protection, in any clinical scenario, is unlikely.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.